Oral and Inhaled Fosamprenavir Reverses Pepsin‐Induced Damage in a Laryngopharyngeal Reflux Mouse Model
- 9 June 2022
- journal article
- research article
- Published by Wiley in The Laryngoscope
- Vol. 133 (S1) , S1-S11
Abstract
Objective: More than 20% of the US population suffers from laryngopharyngeal reflux. Although dietary/lifestyle modifications and alginates provide benefit to some, there is no gold standard medical therapy. Increasing evidence suggests that pepsin is partly, if not wholly, responsible for damage and inflammation caused by laryngopharyngeal reflux. A treatment specifically targeting pepsin would be amenable to local, inhaled delivery, and could prove effective for endoscopic signs and symptoms associated with nonacid reflux. The aim herein was to identify small molecule inhibitors of pepsin and test their efficacy to prevent pepsin‐mediated laryngeal damage in vivo.Methods: Drug and pepsin binding and inhibition were screened by high‐throughput assays and crystallography. A mouse model of laryngopharyngeal reflux (mechanical laryngeal injury once weekly for 2 weeks and pH 7 solvent/pepsin instillation 3 days/week for 4 weeks) was provided inhibitor by gavage or aerosol (fosamprenavir or darunavir; 5 days/week for 4 weeks; n = 3). Larynges were collected for histopathologic analysis.Results: HIV protease inhibitors amprenavir, ritonavir, saquinavir, and darunavir bound and inhibited pepsin with IC50 in the low micromolar range. Gavage and aerosol fosamprenavir prevented pepsin‐mediated laryngeal damage (i.e., reactive epithelia, increased intraepithelial inflammatory cells, and cell apoptosis). Darunavir gavage elicited mild reactivity and no discernable protection; aerosol protected against apoptosis.Conclusions: Fosamprenavir and darunavir, FDA‐approved therapies for HIV/AIDS, bind and inhibit pepsin, abrogating pepsin‐mediated laryngeal damage in a laryngopharyngeal reflux mouse model. These drugs target a foreign virus, making them ideal to repurpose. Reformulation for local inhaled delivery could further improve outcomes and limit side effects.Level of evidence: NA. Laryngoscope, 133:S1–S11, 2023Keywords
Funding Information
- National Institute of General Medical Sciences (R35GM128840)
This publication has 138 references indexed in Scilit:
- Laryngopharyngeal Reflux: Diagnosis, Treatment, and Latest ResearchInternational Archives of Otorhinolaryngology, 2013
- Joint X-ray and neutron refinement withphenix.refineActa Crystallographica Section D Structural Biology, 2010
- Simulated reflux decreases vocal fold epithelial barrier resistanceThe Laryngoscope, 2010
- Features and development of CootActa Crystallographica Section D Structural Biology, 2010
- PHENIX: a comprehensive Python-based system for macromolecular structure solutionActa Crystallographica Section D Structural Biology, 2010
- MolProbity: all-atom structure validation for macromolecular crystallographyActa Crystallographica Section D Structural Biology, 2009
- When Proton Pump Inhibitors FailClinical Gastroenterology and Hepatology, 2008
- Phasercrystallographic softwareJournal of Applied Crystallography, 2007
- Coot: model-building tools for molecular graphicsActa Crystallographica Section D Structural Biology, 2004
- [20] Processing of X-ray diffraction data collected in oscillation mode1997